MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
16 sept. 2021 02h45 HE | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
07 sept. 2021 16h30 HE | MacroGenics, Inc.
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumabOS was greater with MARGENZA plus chemotherapy in exploratory subgroups of...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
25 janv. 2021 07h30 HE | MacroGenics, Inc.
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...